<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04917354</url>
  </required_header>
  <id_info>
    <org_study_id>2017-025</org_study_id>
    <nct_id>NCT04917354</nct_id>
  </id_info>
  <brief_title>Superb Micro-vascular Imaging for Evaluation of Hepatic Lesions</brief_title>
  <official_title>iBEAM-Based Superb Micro-vascular Imaging for Evaluation of Hepatic Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Superb Micro-vascular Imaging (SMI) based on the iBeam platform is used to evaluate the blood&#xD;
      supply of solid tumors. Compared with color Doppler technology, the sensitivity, accuracy and&#xD;
      consistency of the ability of SMI to display blood flow are evaluated. Thus, the&#xD;
      investigators will use Superb-Microvascular imaging (SMI, Toshiba, Japan) for diagnosing&#xD;
      hepatic lesions, which enable to detect slow micro vascular flow inside the tumor&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the diagnostic accuracy of SMI (primary outcome) when applying on the hepatic&#xD;
      lesion.&#xD;
&#xD;
      Each US findings during exam for patients with hepatic lesion were recorded by radiologist.&#xD;
&#xD;
      Sample size calculation according to the primary outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2017</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>diagnostic accuracy</measure>
    <time_frame>1 week preoperatively</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatic Lesion</condition>
  <arm_group>
    <arm_group_label>hepatic lesion</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Superb-Microvascular imaging</intervention_name>
    <description>Device: Superb-Microvascular imaging Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography</description>
    <arm_group_label>hepatic lesion</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The population consisted of patients (age:18-80 years) with visible hepatic lesion on US&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Visible hepatic lesion on US&#xD;
&#xD;
          2. Agree to participate in the study&#xD;
&#xD;
          3. Accessible follow-up imaging or pathological results&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pintong Huang, PhD</last_name>
    <phone>18857168333</phone>
    <email>huangpintong@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The second affilliated hospital of Zhejiang University school of medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Superb Micro-vascular Imaging</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

